Table 6.
Patient | Phase | Treatment | n | OS (mo) | PFS (mo) | RR | DCR |
Second-line treatment for advanced gastric cancer or GEJ adenocarcinoma (REGARD) | III | BSC | 117 | 3.8 | 1.3 | 2.6% | 23.1% |
Ramucirumab | 238 | 5.2 | 2.1 | 3.4% | 48.7% |
BSC: Best supportive care; DCR: Disease control rate; GFJ: Gastroesophageal junction; OS: Overall survival; PFS: Progression-free-survival; RR: Response rate.